Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/9/2015Bioline Launches New JetSeq™ DNA Library Preparation Kit
CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the JetSeq™ DNA Library Preparation Kit, the first product in a new line of kits from Bioline for Next Generation Sequencing (NGS) sample preparation. Developed in collaboration with Oxford Gene Technology (OGT), the JetSeq DNA Library Preparation Kit uses ... 
 Printer Friendly Version
11/18/2015Meridian Receives FDA Clearance for New Molecular Whooping Cough Test Claims
CINCINNATI--(BUSINESS WIRE)--Nov. 18, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for new claims for its illumigene® Pertussis molecular amplification test. The upgraded test reduces the effect of inhibitors in biologic samples and significantly expands Meridian’s customer base by including specimens collected by ESwab™ (Copan Diagnostics, Inc.). ... 
 Printer Friendly Version
11/12/2015Meridian Bioscience Announces Investment in Oasis Diagnostics®
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has made a minority investment in Oasis Diagnostics® Corporation ("Oasis"), with the right to acquire Oasis in the future. The terms of the transaction were not disclosed. Oasis designs, develops, manufactures and sells pre-analytic tools for the collection, preservation, and transportation of saliva/oral fluids. ... 
 Printer Friendly Version
11/5/2015Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2016 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 5, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fourth quarter and record full-year fiscal 2015 net revenues of $47.1 million and $194.8 million, respectively, increases of 1% and 3%, respectively, from the same periods of the prior fiscal year; reported fourth q... 
 Printer Friendly Version
9/9/2015Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2016
CINCINNATI--(BUSINESS WIRE)--Sep. 9, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2016 net revenues and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2016, management expects net revenue growth of 3% to 5% on a constant currency basis, a net revenue range of $195 to $200 million, and per s... 
 Printer Friendly Version
9/4/2015Bioline Launches New EPIK™ miRNA Panel Assays
CINCINNATI--(BUSINESS WIRE)--Sep. 4, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the EPIK™ miRNA Panel Assays, developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of a collaboration between MiRXES in Singapore and Bioline. Using a novel approach developed by MiRXES, comb... 
 Printer Friendly Version
8/17/2015Meridian Bioscience Elects Catherine Sazdanoff and John McIlwraith to the Board of Directors
CINCINNATI--(BUSINESS WIRE)--Aug. 17, 2015-- Meridian Bioscience, Inc. announces that on August 11, 2015, the Board of Directors of Meridian Bioscience, Inc. elected two new independent directors, Catherine A. Sazdanoff and John C. McIlwraith, effective August 14, 2015. Ms. Sazdanoff is the CEO and President of Sazdanoff Consulting LLC, specializing in business development, management and strategy consulting. In addition, she is Strategic ... 
 Printer Friendly Version
7/23/2015Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 23, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: reported fiscal 2015 third quarter and first nine months net revenues of $48.2 million and $147.8 million, respectively, increases of 2% and 4%, respectively, from the same periods of the prior fiscal year; reported third quarter operating i... 
 Printer Friendly Version
7/20/2015Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® HSV 1&2
CINCINNATI--(BUSINESS WIRE)--Jul. 20, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its illumigene® molecular platform. The illumigene® HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the US – they are the eighth and ninth assays added to ... 
 Printer Friendly Version
6/4/2015Meridian Bioscience Launches Para-Pak® SVT (Single Vial Transport)
CINCINNATI--(BUSINESS WIRE)--Jun. 4, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced the launch of Para-Pak® SVT, a one-vial, multi-purpose, transport solution for the collection, transportation, preservation and examination of intestinal parasites in stool specimens. Traditional Ova & Parasite (O&P) examination procedures, as well as fecal antigen immunoassay tests, require different types of preservative... 
 Printer Friendly Version
5/21/2015Meridian Bioscience Europe Launches New Molecular Tests for the Detection of Herpes Simplex Virus Type 1 and Type 2
CINCINNATI--(BUSINESS WIRE)--May 21, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received the CE Mark for new molecular assays for the detection of Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2), to be run on its molecular platform, illumigene®. The HSV 1&2 assays are additions to the portfolio of molecular tests available for use on the illumigene platform; including C. difficile, Chlamydia, Group A Str... 
 Printer Friendly Version
4/23/2015Meridian Bioscience Reports Second Quarter 2015 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Apr. 23, 2015-- Meridian Bioscience, Inc., (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., (NASDAQ: VIVO) today: reported record fiscal 2015 second quarter and first six months net revenues of $51.5 million and $99.6 million, respectively, increases of 3% and 5%, respectively, from the same periods of the prior fiscal year; reported second q... 
 Printer Friendly Version
3/11/2015Bioline Launches Latest ISOLATE II miRNA and RNA Purification Kits
CINCINNATI--(BUSINESS WIRE)--Mar. 11, 2015-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the latest five kits in the high performance ISOLATE II nucleic acid purification range – ISOLATE II miRNA, Plant miRNA, Biofluids RNA, RNA/DNA/Protein, and FFPE RNA/DNA Kits. Based on the latest developments in silica membrane spin column technology and o... 
 Printer Friendly Version
2/26/2015Meridian Bioscience Launches New TRU Brand Test for the Detection of Streptococcus pneumoniae in Urine and CSF
CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announces that it has received the CE Mark for its new test for Streptococcus pneumoniae (S. pneumo). TRU STREP PNEUMO™ is a rapid, qualitative immunoassay for the detection of S. pneumo antigen in urine and CSF and will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the Company’s global distribut... 
 Printer Friendly Version
2/26/2015Meridian Bioscience Receives CE Marking for Two New Molecular Amplification Tests: illumigene® Chlamydia and illumigene® Gonorrhea
CINCINNATI--(BUSINESS WIRE)--Feb. 26, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), the sixth and seventh assays on the illumigene® platform. Along with these two new assays, Meridian also received the CE Mark for an innovative, simple, fast and cost effective sample preparation ... 
 Printer Friendly Version
1/22/2015Meridian Bioscience Reports First Quarter 2015 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 22, 2015-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc. (NASDAQ: VIVO) today: Reported record first quarter net revenues of $48.0 million, an increase of 7% from the same period of the prior fiscal year; reported first quarter operating income of $12.7 million, an increase of 9% from the same period of the prior fisca... 
 Printer Friendly Version
1/9/2015Meridian Opens a New Office in Beijing, China
CINCINNATI--(BUSINESS WIRE)--Jan. 9, 2015-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) has opened a new office in Beijing, China. The office is located on Chang-An Avenue (close to Tiananmen Square and government offices) on the 15th floor in the New China Life Insurance (NCI) Tower Center, in the heart of the central business district (CBD) of Beijing. ... 
 Printer Friendly Version